Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label dose-escalation study of SPK-8011 gene transfer in severe hemophilia A
MOH_2021-11-14_010357Phase 2Not yet recruiting
- Sponsor
- Spark Therapeutics
- Start
- Jul 2021
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of dirloctocogene samoparvovec in hemophilia A (2 cohorts), sponsored by Spark Therapeutics. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
dirloctocogene samoparvovec
03
Conditions
hemophilia A
Beyond the preview
Go deeper on MOH_2021-11-14_010357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-14_010357.